Developing new treatments for complex diseases presents a myriad of challenges, ranging from understanding the disease’s mechanisms to ensuring the […]
Author: Kurt Herpel
Pioneering the Future of Nephrotic Syndrome Research with ARREST-NEPHROSIS
Nephrotic Syndrome affects millions globally, presenting a significant health burden with its hallmark symptoms of severe proteinuria and edema. The […]
Delta4 At BIO-Europe
Delta4 at BIO-Europe 2023: Fostering Partnerships and Driving Innovation We are excited to share Delta4’s presence at the recently concluded […]
What to Expect From The Pharmaceutical Industry In 2024
As we step into 2024, the pharmaceutical industry stands at the cusp of remarkable advancements and significant transformations. This year […]
Digital Health Envision Summit
We are delighted to announce that Dr. Klaus Kratochwill, CSO, and Dr. Paul Perco, Computational Biology Lead of Delta4, are […]
Case Study: Unravelling the Multifaceted Potential of Iguratimod with Delta4’s Hyper-C Platform
Diving deep into the realms of computational drug repurposing, Delta4 leveraged its state-of-the-art Hyper-C platform with an ambitious objective: to […]
Delta4 at RExPO: Pushing the Boundaries of Drug Repurposing
We are thrilled to announce that Delta4 will be in attendance at this year’s RExPO23, a landmark event in the […]
Reactome Spotlights Delta4’s Computational Drug Repositioning of Clopidogrel for FSGS
We are honored to announce that our publication on the computational drug repositioning of clopidogrel has been highlighted in the […]
Delta4 joins the EU-funded COST action PerMediK (Personalized medicine in chronic kidney disease: improved outcome based on Big Data)
The scientific goal of PerMediK is to foster development toward personalized medicine in chronic kidney disease (CKD), based on multidimensional […]
Protected: AI Drug Discovery Services Companies Forging the Future of Medicine
There is no excerpt because this is a protected post.